Page 96 - Read Online

Page 18 of 19 Corn et al. J Cancer Metastasis Treat 2021;7:41 https://dx.doi.org/10.20517/2394-4722.2021.63

95. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-62. DOI PubMed
96. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year
median follow-up study. J Clin Endocrinol Metab 2008;93:3943-9. DOI PubMed
97. Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial
treatment: a systematic review and meta-analysis. Medicine (Baltimore) 2012;91:274-86. DOI PubMed
98. Cuccurullo V, Di Stasio GD, Cascini GL. PET/CT in thyroid cancer - the importance of BRAF mutations. Nucl Med Rev Cent East
Eur 2020;23:97-102. DOI PubMed
99. Pak K, Suh S, Kim SJ, Kim IJ. Prognostic value of genetic mutations in thyroid cancer: a meta-analysis. Thyroid 2015;25:63-70.
DOI PubMed
100. Wang F, Zhao S, Shen X, et al. BRAF V600E confers male sex disease-specific mortality risk in patients with papillary thyroid
cancer. J Clin Oncol 2018;36:2787-95. DOI PubMed PMC
101. Shen X, Zhu G, Liu R, et al. Patient age-associated mortality risk is differentiated by BRAF V600E status in papillary thyroid cancer.
J Clin Oncol 2018;36:438-45. DOI PubMed PMC
102. Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
J Clin Endocrinol Metab 2007;92:2840-3. DOI PubMed
18 V600E
103. Chang JW, Park KW, Heo JH, et al. Relationship between F-fluorodeoxyglucose accumulation and the BRAF mutation in
papillary thyroid cancer. World J Surg 2018;42:114-22. DOI PubMed
104. Choi EK, Chong A, Ha JM, Jung CK, O JH, Kim SH. Clinicopathological characteristics including BRAF V600E mutation status and
PET/CT findings in papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2017;87:73-9. DOI PubMed
105. Morani F, Pagano L, Prodam F, Aimaretti G, Isidoro C. Loss of expression of the oncosuppressor PTEN in thyroid incidentalomas
associates with GLUT1 plasmamembrane expression. Panminerva Med 2012;54:59-63. PubMed
106. Morani F, Phadngam S, Follo C, et al. PTEN regulates plasma membrane expression of glucose transporter 1 and glucose uptake in
thyroid cancer cells. J Mol Endocrinol 2014;53:247-58. DOI PubMed
107. Samih N, Hovsepian S, Aouani A, Lombardo D, Fayet G. Glut-1 translocation in FRTL-5 thyroid cells: role of phosphatidylinositol
3-kinase and N-glycosylation. Endocrinology 2000;141:4146-55. DOI PubMed
108. Matsuzu K, Segade F, Wong M, Clark OH, Perrier ND, Bowden DW. Glucose transporters in the thyroid. Thyroid 2005;15:545-50.
DOI PubMed
109. Matsuzu K, Segade F, Matsuzu U, Carter A, Bowden DW, Perrier ND. Differential expression of glucose transporters in normal and
pathologic thyroid tissue. Thyroid 2004;14:806-12. DOI PubMed
110. Kim BH, Kim IJ, Kim SS, Kim SJ, Lee CH, Kim YK. Relationship between biological marker expression and fluorine-18
fluorodeoxyglucose uptake in incidentally detected thyroid cancer. Cancer Biother Radiopharm 2010;25:309-15. DOI PubMed
111. Ohba K, Sasaki S, Oki Y, et al. Factors associated with fluorine-18-fluorodeoxyglucose uptake in benign thyroid nodules. Endocr J
2013;60:985-90. DOI PubMed
112. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and
recommendations to users. Hum Mutat 2002;19:607-14. DOI PubMed
113. Ghanem M, Levy Y, Mazeh H. Preoperative diagnosis of benign thyroid nodules with intermediate cytology. Gland Surg 2012;1:89-
91. DOI PubMed PMC
114. Alexander EK, Schorr M, Klopper J, et al. Multicenter clinical experience with the afirma gene expression classifier. J Clin
Endocrinol Metab 2014;99:119-25. DOI PubMed
115. Nikiforov YE, Carty SE, Chiosea SI, et al. Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis
in thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology. Thyroid
2015;25:1217-23. DOI PubMed PMC
116. Steward DL, Carty SE, Sippel RS, et al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate
cytology: a prospective blinded multicenter study. JAMA Oncol 2019;5:204-12. DOI PubMed PMC
117. Labourier E, Shifrin A, Busseniers AE, et al. Molecular testing for miRNA, mRNA, and DNA on fine-needle aspiration improves the
preoperative diagnosis of thyroid nodules with indeterminate cytology. J Clin Endocrinol Metab 2015;100:2743-50. DOI PubMed
PMC
18
118. Endo M, Sipos JA, Ringel MD, et al. Prevalence of cancer and the benign call rate of afirma gene classifier in F-
Fluorodeoxyglucose positron emission tomography positive cytologically indeterminate thyroid nodules. Cancer Med 2021;10:1084-
90. DOI PubMed PMC
119. Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with
thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and
differentiated thyroid cancer. Thyroid 2016;26:1-133. DOI PubMed PMC
120. N C C N C l i n i c a l p r a c t i c e g u i d e l i n e s i n o n c o l o g y : t h y r o i d c a r c i n o m a 2 0 2 0 . A v a i l a b l e f r o m :
https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf [Last accessed on 3 Aug 2021].
121. Amin F, Byrd DR, Brookland PK, et al. AJCC cancer staging manual. 8th ed. New York: Springer International Publishing, 2017.
122. Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials. Eur J Surg Oncol
2018;44:307-15. DOI PubMed
123. Nguyen XV, Job J, Fiorillo LE, Sipos J. Thyroid incidentalomas: practice considerations for radiologists in the age of incidental
findings. Radiol Clin North Am 2020;58:1019-31. DOI PubMed
124. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract 2000;6:469-76.